---
title: "Immunic (Nasdaq: IMUX) to join investor conferences in March, focusing on oral therapies for neurologic and gastrointestinal diseases."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277614659.md"
description: "On March 3, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech company specializing in advanced oral treatments for neurological and gastrointestinal conditions, revealed their involvement in investor conferences during March."
datetime: "2026-03-03T11:32:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277614659.md)
  - [en](https://longbridge.com/en/news/277614659.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277614659.md)
---

# Immunic (Nasdaq: IMUX) to join investor conferences in March, focusing on oral therapies for neurologic and gastrointestinal diseases.

On March 3, 2026, Immunic, Inc. (Nasdaq: IMUX), a leading biotech company specializing in advanced oral treatments for neurological and gastrointestinal conditions, revealed their involvement in investor conferences during March.

### Related Stocks

- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md)
- [<![CDATA[FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment ]]>](https://longbridge.com/en/news/282567251.md)
- [08:00 ETLynk Pharmaceuticals Announces NDA Acceptance for Zemprocitinib by NMPA](https://longbridge.com/en/news/282340368.md)